Acute Coronary Syndrome News and Research

RSS

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

16 Mar 2011

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, today announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome.

15 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

LUMEDX implements HealthView Chest Pain Management solution at Methodist hospitals

LUMEDX Corporation, a leading provider of fully integrated, vendor-neutral cardiovascular imaging and information systems, announced today that it has begun implementing the HealthView Chest Pain Management solution at five Methodist Healthcare facilities in San Antonio, Texas.

9 Mar 2011

Miracor completes PICSO System pilot study in patients with ACS

Miracor Medical Systems GmbH announced today the successful completion of the pilot study of its PICSO System, designed to improve acute coronary syndrome revascularization following primary percutaneous coronary intervention.

4 Mar 2011

Mother’s stroke history can help predict daughter’s risk of heart attack

If you're a woman and your mother had a stroke, you may have a risk of heart attack in addition to a higher risk of stroke, according to new research on family history and heart disease published in the American Heart Association journal Circulation: Cardiovascular Genetics.

2 Feb 2011

Employees with heart attack, ACS are major source of health costs

Employees with myocardial infarction and other types of acute coronary syndrome are a major source of direct and indirect health costs, reports a study in the January Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

21 Jan 2011

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

21 Jan 2011

Grayscale IVUS and VH IVUS tissue characterization software help accurate assessment of blockage risk

Volcano Corporation today announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano's proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care-- angiographic imaging-- alone.

20 Jan 2011

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.

20 Jan 2011

Merck announces changes in vorapaxar clinical studies

Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.

14 Jan 2011

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents and the accompanying requirement of long-term dual antiplatelet therapy showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention.

11 Jan 2011

Miracor’s PICSO System may help advance heart failure treatment

Miracor Medical Systems GmbH announced today that its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System, designed to improve outcomes for acute coronary syndrome (ACS) and heart failure patients, has been cited as a technology that "may advance heart failure (HF) treatment significantly".

10 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Risk-adjusted TTR appears to improve anticoagulation control

Researchers from Boston University School of Medicine and the Bedford VA Medical Center believe that risk-adjusted percent time in therapeutic range should be used as part of an effort to improve anticoagulation control and thus improve patient outcomes.

4 Jan 2011

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.

3 Jan 2011

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Opsens Inc. today unveiled the EasyWire, developed by its medical division for the growth market of Fractional Flow Reserve for coronary lesion assessment.

20 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010